Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid by Tisell, L E et al.
Neuroendocrine tumours, including thyroid tumours such as
medullary thyroid carcinoma (MTC), have been shown to express
somatostatin receptors (sstr) and can thus be diagnosed by scinti-
graphic techniques utilizing a radiolabelled somatostatin analogue,
111In-DTPA-D-Phe1-octreotide (Baudin et al, 1996; Tisell et al,
1997). Five different subtypes of sstr have been cloned and shown
to be G-protein coupled receptors with seven transmembrane
regions. Sstr2–3 and sstr5 differ from sstr1 and sstr4 regarding
amino acid homology and pharmacological profile. Octreotide binds
with highest affinity to sstr2 and with lower affinity to sstr3 and
sstr5, while somatostatin binds to all subtypes with high affinity (cf.
Bruns et al, 1994). In patients with differentiated thyroid (non-
MTC) tumours distant metastases can sometimes be diagnosed and
treated with radioiodine. However, one third of these tumours do not
accumulate radioiodine (Maxon et al, 1990). Hürthle (oncocytic)
cell lesions (nodule/adenoma/carcinoma) belong to this category.
The diagnosis of Hürthle cell lesions is today based upon preopera-
tive cytology, or histopathological examination of surgical speci-
mens, demonstrating oncocytic cell features.
The aims of the present study were to compare the outcome of
111In-DTPA-D-Phe1-octreotide scintigraphy with clinical findings
in patients with Hürthle cell lesions of the thyroid and to study the
expression of sstr in these lesions by Northern blotting using
subtype-specific probes. Furthermore, the 111In concentrations in
tumour or normal tissue (Ti) and blood (B) were determined.
MATERIALS AND METHODS
Patients
During a 3-year period (1995–97) 10 patients (seven women and
three men, mean age 68, range 37–86 years) underwent thyroid
surgery with subsequent histological demonstration of Hürthle cell
lesions. All lesions were reexamined by two pathologists (ON and
JM) and classified according to strict criteria (Rosai et al, 1990) as
Hürthle cell nodules (n = 2), Hürthle cell adenoma (n = 4) and
Hürthle cell carcinoma (n = 4) (Table 1). Eight of these patients
had palpable thyroid tumours, where preoperative fine needle aspi-
ration indicated Hürthle cell neoplasia (seven patients) or follic-
ular thyroid neoplasia (one patient). Two patients had previously
been treated for Hürthle cell carcinoma and had metastatic disease
(patient nos V and IX). Patient no. V had local symptoms and
underwent palliative resection, while patient no. IX had no further
treatment. All patients underwent scintigraphy with 111In-
octreotide, and eight patients were also investigated by conven-
tional thyroid scintigraphy (cf. below) prior to surgery (Table 1).
111In concentrations were determined in both tumour and normal
tissues from five patients (Figure 1). Tumour biopsies from four
patients (I–IV, two adenomas, one nodule and one carcinoma, cf.
Table 1) were investigated by Northern analysis and compared
with biopsies of histologically normal thyroid tissue from the
contralateral lobe of two patients, who underwent hemithyroid-
ectomy for benign adenomas.
Scintigraphy
Ten patients received i.v. 210–230 MBq 111In-DTPA-D-Phe1
octreotide (10–20 mg) (Mallinckrodt, The Netherlands). The
amount of 111In bound to octreotide was higher than 98%. Imaging
was done 24–48 h after injection of the radiopharmaceutical. A
gamma camera (GE 400 AC/T), equipped with a medium energy
parallel hole collimator and connected to a GE STARCAM
computer system, was used. Data acquisition was done in a dual
window setting (173 and 247 keV). Single photon emission
computed tomography (SPECT) of the thoracic cage was
performed in all patients (cf. Ahlman et al, 1994). Six patients also
underwent thyroid scintigraphy using 99mTc-pertechnetate (75 MBq)
and the two patients with distant metastases were scanned with 
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Correspondence to: LE Tisell131I (100 MBq). These two patients with previous thyroidectomy
(nos V and IX) were on thyroxin substitution, which was main-
tained during 111In-DTPA-D-Phe1-octreotide scintigraphy, but
discontinued for the radioiodine examination.
Measurement of 111In concentration in tissue samples
and blood
Surgery was performed 5–7 days after injection of 111In-DTPA-D-
Phe1-octreotide. The surgical specimens from tumour and normal
tissues and blood samples, taken during surgery, were weighed and
the  111In concentrations were measured in a calibrated gamma
counter equipped with a NaI(T1) well crystal (diameter 7.6 cm,
length 7.6 cm, Harshaw, The Netherlands) and a single-channel
pulse-height analyser (Elscint, Israel). Corrections were made for
background activity and radioactive decay. Tissue-to-blood 111In
concentration ratios (Ti/B), were calculated for biopsied tissues,
which were subsequently sent for histopathological examination
(cf. Forssell-Aronsson et al, 1995). Tumour biopsies were
included in the analysis, if the biopsy contained more than 80%
tumour tissue. Nonthyroid specimens (lymph nodes, muscle, soft
tissue and fat) were included, if they were tumour-free and
contained less than 20% of adherent tissue.
Northern analyses of sstr 1–5 mRNA expression
Fresh tumour specimens were rapidly frozen in liquid nitrogen.
RNA was prepared by acid guanidine thiocyanate–phenol–chloro-
form extraction. Samples of total RNA (20 mg) were heat-dena-
tured and electrophoresed in a 1% agarose gel with 2.2 mol l–1
formaldehyde, 1 mmol l–1 EDTA, 5 mmol l–1 sodium acetate and
20 mmol l–1 morpholine propane sulphonic acid (pH 7.0) as
running buffer. RNA was transferred to positively charged nylon
membranes (Boehringer, Mannheim, FRG) using a vacuum
transfer system (Hybaid, Middlesex, UK) and crosslinked to the
membrane by UV-light (Stratalinker, Stratagene, La Jolla, CA).
Membranes were hybridized in rotating flasks at 65°C (Hybaid,
Middlesex, UK) using 32P-labelled antisense RNA probes. The
following probes were used: (1) a 1.126 bp PCR fragment of the
human  sstr1 gene corresponding to nucleotides 352–1478
(Yamada et al, 1992a); (2) a 1.7 kb Bam HI/Hind III cDNA frag-
ment of the human sstr2 (Yamada et al, 1992a); (3) a 1.9 kb
Nco/Hind III cDNA fragment of the human sstr3 (Yamada et al,
1992b); (4) a 2.0 kb Nae I/Xbal cDNA fragment of the human
sstr4 (Rohrer et al, 1993); (5) a 1.6 kb Eco R1/Sal III cDNA frag-
ment of the human sstr5 (Yamada et al, 1993), and (6) a 982 bp
fragment of human G3PDH.
Specific labelling was detected after 3–6 days exposure on an
imaging plate, followed by reading in a Phosphor Imager
(Molecular Dynamics, Sunnyvale, CA).
RESULTS
Scintigraphy
The six patients subjected to 99mTc-scintigraphy had thyroid
tumours that were cold. In the two patients with previous
thyroidectomy no metastases could be identified by 131I-scintig-
raphy.  111In-DTPA-D-Phe1-octreotide scintigraphy localized the
Hürthle cell lesions as distinct areas of increased uptake of
radionuclide in all 10 patients (Figure 2A and B; Table 1). In
patient no. V with recurrent metastatic disease site localization
was obtained by 111In-DTPA-D-Phe1-octreotide in the right low
neck region prior to surgery. Multiple lung metastases were also
visualized in this patient as well as in patient no. IX (Figure 2C).
111In concentration in tissue samples
Ti/B ratios of removed Hürthle cell lesions from five patients
(Figure 1) showed large interindividual variations (range 45–94),
but were clearly higher than the Ti/B ratios observed for normal
soft tissue, muscle and fat (range 0.8–3.6). Lymph nodes (all
without tumour involvement) had values ranging from 1.4 to 12.
Normal thyroid tissue had similar values as lymph nodes (Figure
1). Higher levels were observed in parts of the glands with colloid
goiter (range 26–35).
Patient no. III with Hürthle cell adenoma underwent total
thyroidectomy with lymph node dissection on clinical suspicion of
a carcinoma. The histopathological examination demonstrated a
Hürthle cell adenoma in a thyroid gland with areas of colloid
goiter. The Ti/B ratio of the adenoma was higher (45) than the Ti/B
ratios found in the contralateral (26, 32) and pyramidal (34) lobes
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Figure 1 Tissue to blood (Ti/B) 111In activity concentration ratios for Hürthle
cell lesions of the thyroid (N = nodule, A = adenoma and C = carcinoma) in
comparison with various normal tissues. All normal tissues had much lower
values than the Hürthle cell lesions and colloid goiter. No evident differences
were seen between malignant and benign lesions. Roman numerals refer to
patients presented in Table 1
Table 1 Results of scintigraphy in patients with Hürthle cell tumours
Patient Age (years) Tumour type 99mTc 111In
and sex
I 86 F Carcinoma Not done Hot
II 83 F Nodule Cold Hot
III 72 F Adenoma Cold Hot
IV 46 M Adenoma Cold Hot
V 74 F Carcinoma dist met No uptakea Hot
VI 50 F Adenoma Cold Hot
VII 37 M Carcinoma Cold Hot
VIII 78 F Adenoma Cold Hot
IX 75 M Carcinoma dist met No uptakea Hot
X 78 F Nodule Not done Hot
aScintigraphy with 131I.with goiter tissue. Fourteen tumour-free lymph nodes were
removed with much lower Ti/B values (range 1.4–12).
Northern analysis
sstr mRNA was detected in all Hürthle cell lesions investigated as
well as in normal thyroid tissue. Patient no. I with Hürthle cell carci-
noma and patient no. II with a Hürthle cell nodule expressed mRNA
for all five sstr. The two adenoma patients (nos III and IV) had
similar receptor-profiles except for a lack of sstr2. In the controls the
normal thyroid tissue selectively lacked sstr2 (Figure 3; Table 2).
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Figure 2 (A and B) Anteroposterior views of the thyroid scintigraphically
visualized after injection of 99mTc-pertechnetate, pinhole collimator (left lane)
or 111In-DTPA-D-Phe1-octreotide (right lane). A illustrates patient no. VI with a
Hürthle cell adenoma in the right lobe and B patient no. VII with a Hürthle cell
carcinoma in the left lobe. The lesions appeared as cold nodules at 99mTc-
scintigraphy and demonstrated uptake at octreotide scintigraphy. 
(C) Anteroposterior views of the neck and thorax 24 h after injection of 111In-
DTPA-D-Phe1-octreotide in patient no. V with previous thyroidectomy due to
Hürthle cell carcinoma. A large tumour mass is visualized in the right lower
neck/upper mediastinum besides multiple lung metastases
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Figure 3 Northern analysis of sstr expression in Hürthle cell lesions with
positive octreotide scintigraphy in comparison with normal thyroid tissue. The
Hürthle cell lesions expressed 4–5 of the 5 identified sstr subtypes. The
control tissues showed selective lack of sstr 2. The size of mRNA transcripts
is indicated to the right. Membranes were rehybridized with G3PDH to verify
the integrity of RNA transferred to the membranes. Table 2 is a schematic
summary of the results. Roman numerals refer to patients presented in
Table 1
Table 2 Expression of somatostatin receptor subtypes in Hürthle cell lesions and in normal thyroid tissue
Patient Tumour type Expression of somatostatin receptor subtypes
sstr1 sstr2 sstr3 sstr4 sstr5
I Carcinoma + + + + +
II Nodule + + + + +
III Adenoma + – + + +
IV Adenoma + – + + +
Control Normal thyroid + – + + +
Control Normal thyroid + – + + +DISCUSSION
In a previous study of 21 nonmedullary thyroid carcinomas (papil-
lary, follicular and anaplastic tumour types) 111In-DTPA-D-Phe1-
octreotide scintigraphy visualized specific uptakes in all patients with
primary tumours and in 75% of the metastatic lesions. The examina-
tion gave additional information to radioiodine scintigraphy, espe-
cially with regard to skeletal metastases. However, radioiodine
seemed to be superior in detecting pulmonary metastases (Postema et
al, 1996). To our knowledge, octreotide scintigraphy has not previ-
ously been evaluated for Hürthle cell lesions of the thyroid.
In this study 10 patients with Hürthle cell lesions were subjected
to octreotide scintigraphy. The primary lesions, or distant metas-
tases, were in each case localized as distinct areas of increased
111In uptake. Eight patients were investigated by other scinti-
graphic techniques (99mTc; n = 6 and 131I; n = 2). In six patients
subjected to 99mTc-scintigraphy the thyroid lesion appeared as a
cold nodule. In our series two patients with previous thyroidec-
tomy due to Hürthle cell carcinoma had their pulmonary metas-
tases revealed by 111In-DTPA-D-Phe1-octreotide scintigraphy, but
not by 131I scanning. Using double-phase scintigraphy with 99mTc-
sestamibi (MIBI) Vattimo et al (1995) reported visualization of
primary Hürthle cell tumours. In many centres double-phase MIBI
scintigraphy may serve as the first alternative in the evaluation of
cold thyroid nodules or metastases. However, octreotide scintig-
raphy has the advantage that outcome of surgery can be assessed
by one single preoperative injection of 111In-DTPA-D-Phe1-
octreotide also used for postoperative imaging (Ahlman et al,
1994). It is important to evaluate the future role of octreotide
scintigraphy in patients with Hürthle cell lesions in a prospective
study of scintigraphically cold nodules and to investigate whether
radiation therapy mediated via sstr can be an alternative in dissem-
inated disease (cf. Wängberg et al, 1997). One advantage with
both octreotide- and MIBI-scintigraphy is that thyroid substitution
therapy does not have to be withdrawn before the examinations.
The visualization of Hürthle cell lesions by octreotide scintig-
raphy is most likely due to a higher number of sstr in the lesions
compared with normal thyroid tissue. The receptor-subtype
profiles may also influence the visualization, because octreotide
has different affinities for the various sstr-subtypes (Bruns et al,
1994). Very similar receptor profiles were observed in normal
thyroid and tumour tissues by Northern blotting, which indicates
that octreotide imaging in these thyroid tumours is not due to a
change in receptor profile, but rather to an increased number of
sstr. A differential diagnostic problem is illustrated by patient no.
III with a relatively high uptake of 111In in nontumour thyroid
tissue. The uptake of 111In in the colloid goiter tissue may represent
binding to thyreocytes and lymphocytes. There was no obvious
difference between the uptake in Hürthle cells of nodules,
adenomas or carcinomas. Uptake of 111In in the thyroid in benign
conditions (endemic colloid goiter, thyroid autonomy and Grave’s
disease) has been reported previously (Becker et al, 1995). The
relative high uptake of 111In in colloid goiter tissue may lead to
misinterpretations. The main indication for octreotide scintigraphy
in patients with Hürthle cell tumour is therefore suspicion of
metastatic disease.
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